OverviewChartNewsTraderScreen

BVT Knock-Out GNMSF/  DE000VE954G5  /

Frankfurt Zert./VONT
14/05/2024  10:21:52 Chg.+0.510 Bid13:30:19 Ask13:30:19 Underlying Strike price Expiration date Option type
9.450EUR +5.70% 9.430
Bid Size: 8,000		 9.450
Ask Size: 8,000		 Genmab A/S 1,337.18 DKK 31/12/2078 Call
GlobeNewswire 13:00 Immatics Announces First Quarter 2024 Financial Results and Business Update
GlobeNewswire 06/05 BioNTech Announces First Quarter 2024 Financial Results and Corporate Update
GlobeNewswire 02/05 Genmab Announces Financial Results for the First Quarter of 2024
GlobeNewswire 30/04 TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervica...
GlobeNewswire 22/04 BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024
GlobeNewswire 07/04 Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persis...
GlobeNewswire 03/04 Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
GlobeNewswire 20/03 BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
GlobeNewswire 20/03 BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer
GlobeNewswire 11/03 BioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidat...
GlobeNewswire 07/03 BioNTech Announces Planned Retirement of Sean Marett
GlobeNewswire 06/03 BioNTech to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update ...
GlobeNewswire 04/03 Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of ...
GlobeNewswire 14/02 Genmab Announces Initiation of Share Buy-Back Program
GlobeNewswire 14/02 Genmab Publishes 2023 Annual Report
GlobeNewswire 08/02 BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Exp...
GlobeNewswire 08/02 BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Exp...
GlobeNewswire 31/01 BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjuga...
GlobeNewswire 22/01 BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/...
GlobeNewswire 09/01 BioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire 21/12/2023 BioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Can...
GlobeNewswire 18/12/2023 BioNTech Achieves Milestone at mRNA-based Vaccine Manufacturing Site in Rwanda
GlobeNewswire 12/12/2023 BioNTech to Inaugurate First African Site on December 18, 2023
GlobeNewswire 09/11/2023 Major Shareholder Announcement
GlobeNewswire 08/11/2023 Major Shareholder Announcement